News

Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update

WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated…

2 years ago

Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease

Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc.…

2 years ago

Cytek Biosciences Appoints Todd Garland Chief Commercial Officer

Industry Seasoned Executive Joins CytekFREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell…

2 years ago

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology…

2 years ago

Alignment Healthcare to Participate in BofA Securities 2022 Healthcare Conference

ORANGE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled…

2 years ago

ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the…

2 years ago

PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates

REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing…

2 years ago

Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN

Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor cellsPreclinical data shows proof-of-principle that…

2 years ago

New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022

Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing forms of Leber congenital amaurosisRALEIGH,…

2 years ago

Virax Biolabs Announces the Appointment of Jason D. Davis as Chief Financial Officer

London, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) -- Virax Biolabs Group Limited (“Virax” or the “Company”) is pleased to…

2 years ago